Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating human disease.

Complementary discoveries have the potential to enhance treatment options for antibiotic-resistant infections. Researchers at ...

CAR T cell therapy is one of the most promising new cancer treatments to emerge in recent years. It involves removing a patient's own immune T cells and engineering them to recognize specific targets ...

The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trading higher Friday following two major developments that strengthen ...

Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

Vertex Pharmaceuticals (VRTX) stock gains as England opts to reimburse its CRSPR (CRSP)-partnered gene therapy Casgevy to ...

The gene therapy Casgevy, which will now be offered to some patients in England, could help people live disease-free, experts ...

Vertex Pharmaceuticals Inc. (VRTX), a commercial-stage global biotechnology company, announced Friday a reimbursement agreement with ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

NHS officials estimate that around 50 people a year will receive treatment now that it has been approved for use for certain ...